|
Oct 9
|
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
|
Aug 18
|
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Jul 25
|
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
|
|
Jun 26
|
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
|
|
Apr 1
|
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
|
|
Dec 22
|
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
|
|
Dec 18
|
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
|
|
Dec 12
|
Cyclacel Pharmaceuticals Announces Reverse Stock Split
|
|
Nov 30
|
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
|
|
Nov 29
|
Health Care Roundup: Market Talk
|
|
Nov 28
|
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
|
|
Nov 14
|
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
|
|
Nov 13
|
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
|
|
Nov 7
|
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
|
|
Aug 10
|
Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call
|
|
Aug 9
|
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
|